FWBI vs. XBIO, CVKD, AIMD, PTIX, HOTH, VCNX, ATXI, ADXS, HILS, and SHPH
Should you be buying First Wave BioPharma stock or one of its competitors? The main competitors of First Wave BioPharma include Xenetic Biosciences (XBIO), Cadrenal Therapeutics (CVKD), Ainos (AIMD), Protagenic Therapeutics (PTIX), Hoth Therapeutics (HOTH), Vaccinex (VCNX), Avenue Therapeutics (ATXI), Ayala Pharmaceuticals (ADXS), Hillstream BioPharma (HILS), and Shuttle Pharmaceuticals (SHPH). These companies are all part of the "pharmaceutical preparations" industry.
First Wave BioPharma (NASDAQ:FWBI) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.
First Wave BioPharma has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.6, suggesting that its share price is 160% more volatile than the S&P 500.
Xenetic Biosciences received 164 more outperform votes than First Wave BioPharma when rated by MarketBeat users. Likewise, 68.24% of users gave Xenetic Biosciences an outperform vote while only 45.45% of users gave First Wave BioPharma an outperform vote.
In the previous week, First Wave BioPharma had 2 more articles in the media than Xenetic Biosciences. MarketBeat recorded 3 mentions for First Wave BioPharma and 1 mentions for Xenetic Biosciences. First Wave BioPharma's average media sentiment score of 0.00 beat Xenetic Biosciences' score of -1.00 indicating that First Wave BioPharma is being referred to more favorably in the media.
12.3% of First Wave BioPharma shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 0.5% of First Wave BioPharma shares are owned by company insiders. Comparatively, 9.0% of Xenetic Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
First Wave BioPharma has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -162.84%. Xenetic Biosciences' return on equity of -36.43% beat First Wave BioPharma's return on equity.
First Wave BioPharma currently has a consensus target price of $118.00, indicating a potential upside of 4,222.34%. Given First Wave BioPharma's stronger consensus rating and higher possible upside, equities analysts plainly believe First Wave BioPharma is more favorable than Xenetic Biosciences.
Xenetic Biosciences has higher revenue and earnings than First Wave BioPharma. Xenetic Biosciences is trading at a lower price-to-earnings ratio than First Wave BioPharma, indicating that it is currently the more affordable of the two stocks.
Summary
Xenetic Biosciences beats First Wave BioPharma on 10 of the 17 factors compared between the two stocks.
Get First Wave BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for FWBI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FWBI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
First Wave BioPharma Competitors List
Related Companies and Tools
